A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension.

导出 LinkOut

翻译打印收藏纠错

作者： Hiromi,Rakugi ^[1] ; Kohei,Shimizu ^[2] ; Yuya,Nishiyama ^[2] ; Yuhei,Sano ^[2] ; Yuusuke,Umeda ^[2]

作者单位： a Department of Geriatric and General Medicine , Osaka University Graduate School of Medicine , Osaka , Japan. ^[1] b Takeda Development Center Japan , Takeda Pharmaceutical Company Limited , Osaka , Japan. ^[2]

关键词 Azilsartan Hypertension amlodipine angiotensin II receptor blocker (ARB)calcium channel blocker (CCB)diuretic hydrochlorothiazide triple combination therapy

主题词成年人(Adult);老年人(Aged);氨氯地平(Amlodipine);苯咪唑类(Benzimidazoles);血压(Blood Pressure);用药计划表(Drug Administration Schedule);药物疗法, 联合(Drug Therapy, Combination);女(雌)性(Female);人类(Humans);氢氯噻嗪(Hydrochlorothiazide);男(雄)性(Male);中年人(Middle Aged);恶二唑类(Oxadiazoles)

DOI 10.1080/08037051.2017.1412797

PMID 29235365

发布时间 2018-11-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览8

Blood pressure

2018年27卷3期

125-133页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension.

Blood pressure

相似文献

Blood pressure

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension.

Blood pressure

相似文献

Blood pressure

相关期刊

检索历史清除